| Transcriptional mediators of treatment resistance in lethal prostate cancer MX He, MS Cuoco, J Crowdis, A Bosma-Moody, Z Zhang, K Bi, A Kanodia, ... Nature medicine 27 (3), 426-433, 2021 | 112 | 2021 |
| Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... Nature communications 12 (1), 808, 2021 | 98 | 2021 |
| Detection of pathogenic variants with germline genetic testing using deep learning vs standard methods in patients with prostate cancer and melanoma SH AlDubayan, JR Conway, SY Camp, L Witkowski, E Kofman, ... Jama 324 (19), 1957-1969, 2020 | 37 | 2020 |
| Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer AK Tewari, ATM Cheung, J Crowdis, JR Conway, SY Camp, ... Cell Reports 36 (10), 2021 | 30 | 2021 |
| Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes R Gillani, SY Camp, S Han, JK Jones, H Chu, S O’Brien, EL Young, ... The American Journal of Human Genetics 109 (6), 1026-1037, 2022 | 25 | 2022 |
| Altered regulation of DPF3, a member of the SWI/SNF complexes, underlies the 14q24 renal cancer susceptibility locus LM Colli, L Jessop, TA Myers, SY Camp, MJ Machiela, J Choi, R Cunha, ... The American Journal of Human Genetics 108 (9), 1590-1610, 2021 | 14 | 2021 |
| Evaluating the molecular diagnostic yield of joint genotyping–based approach for detecting rare germline pathogenic and putative loss-of-function variants SY Camp, E Kofman, B Reardon, ND Moore, AM Al-Rubaish, M Aljumaan, ... Genetics in Medicine 23 (5), 918-926, 2021 | 7 | 2021 |
| A patient-driven clinicogenomic partnership for metastatic prostate cancer J Crowdis, S Balch, L Sterlin, BS Thomas, SY Camp, M Dunphy, ... Cell genomics 2 (9), 2022 | 5 | 2022 |
| Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint Inhibitors Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... bioRxiv, 2020.05. 28.121806, 2020 | 4 | 2020 |
| Overcoming barriers to tumor genomic profiling through direct-to-patient outreach SA Doe-Tetteh, SY Camp, D Reales, J Crowdis, AM Noronha, B Wolff, ... Clinical Cancer Research 29 (13), 2445-2455, 2023 | 3 | 2023 |
| Mutational footprint of platinum chemotherapy in a secondary thyroid cancer J Schiantarelli, T Pappa, J Conway, J Crowdis, B Reardon, F Dietlein, ... JCO Precision Oncology 6, e2200183, 2022 | 2 | 2022 |
| A patient-driven clinicogenomic partnership through the Metastatic Prostate Cancer Project J Crowdis, S Balch, L Sterlin, BS Thomas, SY Camp, M Dunphy, ... bioRxiv, 2021.07. 09.451849, 2021 | 2 | 2021 |
| Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma SH Han, SY Camp, H Chu, R Collins, R Gillani, J Park, Z Bakouny, ... European Urology Open Science 62, 107-122, 2024 | 1 | 2024 |
| Interplay of Mendelian and polygenic risk factors in Arab breast cancer patients M Al-Jumaan, H Chu, A Alsulaiman, SY Camp, S Han, R Gillani, ... Genome Medicine 15 (1), 65, 2023 | 1 | 2023 |
| Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms. C Labaki, L Zhang, Y Hou, K Bi, C Hobeika, Z Bakouny, SY Camp, ... Journal of Clinical Oncology 40 (16_suppl), 4549-4549, 2022 | 1 | 2022 |
| Expanding the diagnostic yield of germline genetic testing in cancer patients using deep learning. SH Aldubayan, J Conway, L Witkowski, E Kofman, B Reardon, S Camp, ... Journal of Clinical Oncology 38 (15_suppl), 1518-1518, 2020 | 1 | 2020 |
| MP65-10 SINGLE-CELL ASSAY FOR TRANSPOSASE-ACCESSIBLE CHROMATIN SEQUENCING DEMONSTRATES ACCESSIBILITY OVERLYING GENE PROMOTER REGIONS FOR PREVIOUSLY ESTABLISHED BASAL CELL MARKERS J Egan, J Lee, S Camp, A Garza, J Park, E Van Allen, FLF Carvalho The Journal of Urology 211 (5S), e1080, 2024 | | 2024 |
| Transposable element expression patterns in epigenetic mutational subtypes of clear cell renal cell carcinoma K Meli, CA Ricker, SY Camp, CC Smith, C Labaki, E Saad, H Soulati, ... Cancer Research 84 (6_Supplement), 5673-5673, 2024 | | 2024 |
| Abstract P01: Impact of Germline and Somatic ATM Variants in Chronic Lymphocytic Leukemia (CLL): Clinical Implications and Response to PARP Inhibition K Mashima, N Moore, M Mikhaleva, A Petráčková, S Shupe, ... Blood Cancer Discovery 5 (2_Supplement), P01-P01, 2024 | | 2024 |
| Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC). C Labaki, M Alchoueiry, K Bi, L Zhang, C Hobeika, Z Bakouny, ... Journal of Clinical Oncology 42 (4_suppl), 476-476, 2024 | | 2024 |
